Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
760.300.3%
QQQ
717.870.13%
BTC/USD
80981.256.0676%
DIA
515.880.48%
GLD
402.290.99%
TLT
81.250.65%

TransCode Therapeutics Inc

RNAZNASDAQ
Trade with Public
Trade with Public
$1.61
-0.11-6.4%
Last update: Sep 16, 5:31 PM
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

TransCode Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for TransCode Therapeutics (RNAZ).

Price Target Range — 6 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$280Upside to Avg. PT+17291.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Apr 16, 2025HC Wainwright & Co.Emily BodnarPT CutBuy$20→$10
Mar 13, 2025HC Wainwright & Co.Emily BodnarMaintainedBuy$20
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and lowers the price target from $20 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and raises the price target from $3 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved